Brighton Jones LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 920 shares of the biopharmaceutical company’s stock after buying an additional 14 shares during the quarter. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $967,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Gilbert & Cook Inc. increased its stake in Regeneron Pharmaceuticals by 8.3% during the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after acquiring an additional 146 shares during the last quarter. TrinityPoint Wealth LLC increased its position in Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares in the last quarter. D.A. Davidson & CO. raised its holdings in Regeneron Pharmaceuticals by 17.0% in the fourth quarter. D.A. Davidson & CO. now owns 709 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 103 shares during the period. US Bancorp DE lifted its position in Regeneron Pharmaceuticals by 6.7% during the fourth quarter. US Bancorp DE now owns 4,941 shares of the biopharmaceutical company’s stock valued at $4,340,000 after buying an additional 310 shares in the last quarter. Finally, Commerce Bank grew its stake in Regeneron Pharmaceuticals by 4.3% during the fourth quarter. Commerce Bank now owns 6,217 shares of the biopharmaceutical company’s stock worth $5,460,000 after buying an additional 257 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,145.03 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company’s 50-day simple moving average is $1,131.75 and its 200-day simple moving average is $1,031.74. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The stock has a market capitalization of $126.17 billion, a price-to-earnings ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the company posted $8.79 earnings per share. The firm’s revenue was up 12.3% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Barclays increased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock worth $11,498,705 over the last quarter. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.